Key takeaways
Alogliptin (Nesina) and glyburide (Glynase) are both medications used to treat Type 2 diabetes, but they work in different ways and have distinct characteristics. Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that helps lower blood sugar by allowing insulin to stay in your body longer and reducing sugar production. It is typically taken once daily and is available in a lower-cost generic form. Glyburide is a sulfonylurea that lowers blood sugar by signaling your pancreas to release more insulin. It can be taken once or twice daily, depending on your dose, and also has a generic version. While alogliptin isn't a first-choice treatment and doesn't significantly affect weight, glyburide can lower A1C levels more effectively but carries a higher risk of causing low blood sugar and potential weight gain. Serious side effects of glyburide include severe low blood sugar (hypoglycemia) and possible heart problems, while taking alogliptin may cause issues like severe joint pain and pancreatitis.
